Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Ferdinando Nicoletti | M | - |
OncoNOx ApS
OncoNOx ApS Pharmaceuticals: MajorHealth Technology OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark. | 13 ans |
Maurizio Denaro | M | - |
Natimab Therapeutics Srl
Natimab Therapeutics Srl BiotechnologyHealth Technology Natimab Therapeutics Srl operates as a biotechnology company. It specializes in the identification and early-stage clinical development of monoclonal antibodies (mAbs) for the treatment of infectious diseases. The company was founded by Gianni Garotta, Maurizio Denaro, Marianne Murphy and Gerritt Hagens in 2009 and is headquartered in Colleretto Giacosa, Italy. | 15 ans |
Gerrit Hagens | M | - |
Natimab Therapeutics Srl
Natimab Therapeutics Srl BiotechnologyHealth Technology Natimab Therapeutics Srl operates as a biotechnology company. It specializes in the identification and early-stage clinical development of monoclonal antibodies (mAbs) for the treatment of infectious diseases. The company was founded by Gianni Garotta, Maurizio Denaro, Marianne Murphy and Gerritt Hagens in 2009 and is headquartered in Colleretto Giacosa, Italy. | 15 ans |
Yousef Al-Abed | M | - |
OncoNOx ApS
OncoNOx ApS Pharmaceuticals: MajorHealth Technology OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark. | 13 ans |
Marco Donia | M | - |
OncoNOx ApS
OncoNOx ApS Pharmaceuticals: MajorHealth Technology OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark. | 13 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Mai-Britt Zocca | M | 56 |
OncoNOx ApS
OncoNOx ApS Pharmaceuticals: MajorHealth Technology OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark. | 8 ans |
Hans Schambye | M | 59 |
OncoNOx ApS
OncoNOx ApS Pharmaceuticals: MajorHealth Technology OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark. | - |
Marianne Murphy | M | - |
Natimab Therapeutics Srl
Natimab Therapeutics Srl BiotechnologyHealth Technology Natimab Therapeutics Srl operates as a biotechnology company. It specializes in the identification and early-stage clinical development of monoclonal antibodies (mAbs) for the treatment of infectious diseases. The company was founded by Gianni Garotta, Maurizio Denaro, Marianne Murphy and Gerritt Hagens in 2009 and is headquartered in Colleretto Giacosa, Italy. | - |
Statistiques
Pays | Relations | % du total |
---|---|---|
Danemark | 5 | 62,50% |
Italie | 3 | 37,50% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Gianni Garotta
- Réseau Personnel